Literature DB >> 3182336

Ouabain sensitizes tumor cells but not normal cells to radiation.

T S Lawrence1.   

Abstract

Ouabain is a cardiac glycoside that blocks the sodium, potassium-pump (Na,K-Pump). When A549 human lung adenocarcinoma cells were treated with 10(-6) M ouabain for 4 hr starting 1 hr before irradiation, they were sensitized (enhancement ratio at 1% survival 1.46 +/- .07, N = 5). Ouabain affected radiation repair because it decreased the shoulder of the cell survival curve and it sensitized cells when added after radiation. CCL-210 normal human lung fibroblasts were not radiosensitized by ouabain concentrations from 10(-8) M to 10(-5) M. These results suggest that it may be possible to exploit differences in the Na,K-pumps of normal cells and tumor cells to improve the therapeutic index of radiation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182336     DOI: 10.1016/0360-3016(88)90132-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.

Authors:  Daniel R Wahl; Joseph Dresser; Kari Wilder-Romans; Joshua D Parsels; Shuang G Zhao; Mary Davis; Lili Zhao; Maureen Kachman; Stefanie Wernisch; Charles F Burant; Meredith A Morgan; Felix Y Feng; Corey Speers; Costas A Lyssiotis; Theodore S Lawrence
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

3.  The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.

Authors:  Leslie A Parsels; Joshua D Parsels; Daria M Tanska; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

4.  CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.

Authors:  Svetlana Grabauskiene; Edward J Bergeron; Guoan Chen; Andrew C Chang; Jules Lin; Dafydd G Thomas; Thomas J Giordano; David G Beer; Meredith A Morgan; Rishindra M Reddy
Journal:  Lung Cancer       Date:  2013-09-23       Impact factor: 5.705

5.  Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Authors:  David Karnak; Carl G Engelke; Leslie A Parsels; Tasneem Kausar; Dongping Wei; Jordan R Robertson; Katherine B Marsh; Mary A Davis; Lili Zhao; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Clin Cancer Res       Date:  2014-08-12       Impact factor: 12.531

6.  Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.

Authors:  Leslie A Parsels; Yushen Qian; Daria M Tanska; Marisa Gross; Lili Zhao; Maria C Hassan; Sankari Arumugarajah; Joshua D Parsels; Linda Hylander-Gans; Diane M Simeone; Deborah Morosini; Jeffrey L Brown; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Clin Cancer Res       Date:  2011-04-11       Impact factor: 12.531

7.  Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells.

Authors:  Hosam A Elbaz; Todd A Stueckle; Hua-Yu Leo Wang; George A O'Doherty; David T Lowry; Linda M Sargent; Liying Wang; Cerasela Zoica Dinu; Yon Rojanasakul
Journal:  Toxicol Appl Pharmacol       Date:  2011-10-18       Impact factor: 4.219

8.  PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.

Authors:  Leslie A Parsels; David Karnak; Joshua D Parsels; Qiang Zhang; Jonathan Vélez-Padilla; Zachery R Reichert; Daniel R Wahl; Jonathan Maybaum; Mark J O'Connor; Theodore S Lawrence; Meredith A Morgan
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

Review 9.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.

Authors:  Meredith A Morgan; Leslie A Parsels; Laura E Kollar; Daniel P Normolle; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.